title: Effective case/infection ratio of poliomyelitis in vaccinated populations.
abstract: Recent polio outbreaks in Syria and Ukraine, and isolation of poliovirus from asymptomatic carriers in Israel have raised concerns that polio might endanger Europe. We devised a model to calculate the time needed to detect the first case should the disease be imported into Europe, taking the effect of vaccine coverage - both from inactivated and oral polio vaccines, also considering their differences - on the length of silent transmission into account by deriving an 'effective' case/infection ratio that is applicable for vaccinated populations. Using vaccine coverage data and the newly developed model, the relationship between this ratio and vaccine coverage is derived theoretically and is also numerically determined for European countries. This shows that unnoticed transmission is longer for countries with higher vaccine coverage and a higher proportion of IPV-vaccinated individuals among those vaccinated. Assuming borderline transmission (R = 1·1), the expected time to detect the first case is between 326 days and 512 days in different countries, with the number of infected individuals between 235 and 1439. Imperfect surveillance further increases these numbers, especially the number of infected until detection. While longer silent transmission does not increase the number of clinical diseases, it can make the application of traditional outbreak response methods more complicated, among others.
authors.affiliation: Polymer Chemistry Research Group,Institute of Materials and Environmental Chemistry,Research Centre for Natural Sciences,Hungarian Academy of Sciences,Budapest,Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Bencskó
authors.affiliation: John von Neumann Faculty of Informatics,Physiological Controls Group,Óbuda University,Budapest,Hungary.
authors.forename: T
authors.identifier: 0000-0001-6791-3080
authors.initials: T
authors.lastname: Ferenci
mesh_terms: D004812:Epidemiologic Methods; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D015233:Models, Statistical; D011051:Poliomyelitis / Q000453:epidemiology* / Q000517:prevention & control* / Q000635:transmission; D023321:Poliovirus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D023321:Poliovirus Vaccines
keywords: AFP surveillance; IPV; OPV; case/infection ratio; poliomyelitis; reproduction rate
references.citation: Vaccine. 2011 Oct 26;29(46):8205-14
references.pmid: 21896299
references.citation: Risk Anal. 2013 Apr;33(4):544-605
references.pmid: 22804479
references.citation: Bull World Health Organ. 1985;63(6):1055-68
references.pmid: 3879673
references.citation: BMC Infect Dis. 2009 Sep 30;9:162
references.pmid: 19788763
references.citation: PLoS Pathog. 2012;8(4):e1002599
references.pmid: 22532797
references.citation: Am J Public Health. 2000 Oct;90(10):1515-20
references.pmid: 11029980
references.citation: Lancet. 2013 Nov 30;382(9907):1777
references.pmid: 24211043
references.citation: Am J Epidemiol. 1996 Apr 15;143(8):816-22
references.pmid: 8610692
references.citation: MMWR Morb Mortal Wkly Rep. 2014 Oct 24;63(42):941-6
references.pmid: 25340910
references.citation: Am J Epidemiol. 2010 Dec 1;172(11):1213-29
references.pmid: 20978089
references.citation: MMWR Morb Mortal Wkly Rep. 2015 May 22;64(19):527-31
references.pmid: 25996095
references.citation: Bull World Health Organ. 2009 Jul;87(7):535-41
references.pmid: 19649368
references.citation: MMWR Recomm Rep. 1997 Jan 24;46(RR-3):1-25
references.pmid: 9026708
references.citation: J Infect Dis. 1997 Feb;175 Suppl 1:S141-5
references.pmid: 9203706